Spastic Paraplegia 21 (SPG21) (N-Term) Peptid
SPG21
Reaktivität: Human
Wirt: Synthetic
BP, WB
Produktnummer ABIN5671444
150,78 €
Zzgl. Versandkosten 20,00 € und MwSt
100 μg
Lieferung nach:
Deutschland
Lieferung in 15 bis 22 Werktagen
Kurzübersicht für Spastic Paraplegia 21 (SPG21) (N-Term) Peptid (ABIN5671444)
Target
SPG21
(Spastic Paraplegia 21 (SPG21))
Spezies
Human
Quelle
Synthetic
Applikation
Blocking Peptide (BP), Western Blotting (WB)
-
-
Protein Region
- N-Term
-
Sequenz
- GTVPLKKIIV DDDDSKIWSL YDAGPRSIRC PLIFLPPVSG TADVFFRQIL
-
Produktmerkmale
- This is a synthetic peptide designed for use in combination with anti- SPG21 Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- SPG21 (Spastic Paraplegia 21 (SPG21))
-
Hintergrund
-
The protein encoded by this gene binds to the hydrophobic C-terminal amino acids of CD4 which are involved in repression of T cell activation. The interaction with CD4 is mediated by the noncatalytic alpha/beta hydrolase fold domain of this protein. It is thus proposed that this gene product modulates the stimulatory activity of CD4. Mutations in this gene are associated with autosomal recessive spastic paraplegia 21 (SPG21), also known as mast syndrome. Alternative splicing results in multiple transcript variants.
Alias Symbols: MAST, ACP33, GL010, BM-019
Protein Size: 281 -
Gen-ID
- 51324
-
NCBI Accession
- NM_001127889, NP_001121361
Target
-
Sie sind hier:
